Small cell carcinoma of the bladder and prostate

Abbas, Farhat; Civantos, Francisco; Benedetto, Pasquale; Soloway, Mark S.

doi:10.1016/s0090-4295(99)80290-8

Cited by 170 publications

(159 citation statements)

References 91 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] Because of this low incidence, the published reports on this topic encompass limited numbers of patients (ranging from 5-88), and consensus on the optimal treatment strategy has not been reached. [4][5][6] Initially, radical cystectomy was considered the standard of care for patients with clinically localized disease.…”

Section: Introductionmentioning

confidence: 99%

“…However, the high rate of metastases has led to the introduction of multimodality approaches with systemic chemotherapy combined with either surgery or radiotherapy. [3][4][5][6][7] Recently Koay et al reported on a large subset of patients from the SEER Medicare database with SCCB treated with chemotherapy and radiotherapy versus cystectomy with chemotherapy, showing no significant differences in overall survival between the two treatment modalities. 8 The biological and clinicopathological features of SCCB are similar to those of SCLC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder

et al. 2012

View full text Add to dashboard Cite

Abbreviations & Acronyms AWD = alive with disease AWOD = alive without disease BCG = bacillus Calmette-Guérin CaE = carboplatin/etoposide CDE = cyclophosphamide/ doxorubicine/etoposide CE = cisplatin/etoposide CIS = carcinoma in situ CR = complete response; CSS = cancer-specific survival CT = computed tomography DOD = died of disease DOOD = died of other disease; EBRT = external beam radiotherapy ED = extensive disease ED-SCCB = extensive disease small cell carcinoma of the bladder GC = gemcitabin/cisplatin IQR = interquartile range LD = limited disease LD-SCCB = limited disease small cell carcinoma of the bladder MVAC = methotrexate// vinblastine/doxorubicine/cisplatin OS = overall survival PR = partial response SCC = small cell carcinoma SCCB = small cell carcinoma of the bladder SCLC = small cell lung carcinoma SD = stable disease SEER = Surveillance, Epidemiology and End Results TNM = tumor-nodes-metastasis TUR-BT = transurethral resection of the bladder tumor UCC = urothelial cell carcinoma Objectives: To assess the long-term outcome and the risk for local recurrence of patients with small cell carcinoma of the bladder (SCCB) treated with neoadjuvant chemotherapy followed by external beam radiotherapy (sequential chemoradiation). Methods: All consecutive patients with primary small cell carcinoma of the bladder (n = 66), treated in our institution between 1993 and 2011 were retrospectively evaluated from an institutional database. Only patients with limited disease (Tx-4N0-1M0) small cell carcinoma of the bladder treated with sequential chemoradiation (n = 27) were included in this study. Recurrence rates, overall survival and cancer-specific survival were analyzed using the Kaplan-Meier method. Results: Median time to recurrence was 20 months, median overall survival 26 months, 5-year overall survival 22.2%, median cancer-specific survival 47 months and 5-year cancer-specific survival 39.6%. For complete responders after neoadjuvant chemotherapy (n = 19), median cancer-specific survival was 52 months with a 5-year cancer-specific survival 45.9% versus a median cancer-specific survival of 22 months and 5-year cancer-specific survival 0.0% for incomplete responders (n = 8; P = 0.034). Eight patients (29.6%) underwent transurethral resections (TUR-BT) for local recurrences in the bladder. At the end of follow up, four patients had undergone cystectomy for recurrence of disease resulting in a bladder-preservation rate of 85.2%. Median time to local recurrence was 29 months and median time to distant recurrence was 10 months. Conclusions: Sequential chemoradiation for limited disease small cell carcinoma of the bladder results in a reasonable outcome with a high bladder preservation rate. Response to neoadjuvant chemotherapy represents a significant prognostic factor in this patient population.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder

et al. 2012

View full text Add to dashboard Cite

show abstract

“…22,32 These paraneoplastic syndromes appear less common in SCCB compared to SCC of the lung or prostate. 33 …”

Section: Epidemiology/presentationmentioning

confidence: 99%

Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Moretto

Wood

Emmenegger

et al. 2013

CUAJ

View full text Add to dashboard Cite

“…SCCB similar to its lung counterpart [small cell carcinoma of lung] is a disease making its appearance in advancing age with a male preponderance and is strongly related to cigarette smoking. Contrary to other carcinomas seen in the urinary bladder like transitional cell carcinoma, adenocarcinoma and squamous cell carcinoma, SCCB is characterized by an aggressive behavior, early metastatic incidence (56%), high disease related mortality rate (68.7% within 2 years from the time of diagnosis) with survival rates at the end of second and fifth year being 25% and 8% respectively, rare long term disease free intervals (post treatment) and a median survival of 9.3 months (post treatment) (Blomjous et al, 1989;Oesterling et al, 1990;Lopez et al, 1994;Abbas et al, 1995;Trias et al, 2001;Helpap, 2002).…”

Section: Characteristics Of Sccbmentioning

confidence: 99%

“…Apart from lungs, it is also seen to localize in the urinary bladder, ureters, prostate, kidneys, esophagus, stomach, small intestine, colon and rectum, pancreas, salivary glands, breast, cervix, vagina, pharynx, larynx and skin (Abbas et al, 1995).…”

Section: Introductionmentioning

confidence: 99%

Primary Small Cell Carcinoma of the Urinary Bladder - Mini-review of the Literature

Chhabra

Hegde

Singhal³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Primary small cell carcinoma of urinary bladder is a rare but aggressive disease with poor prognosis and a high mortality rate. It accounts for less than 1 % of all the primary cancers seen in the urinary bladder. Diagnosis and management of this entity poses a challenge to the clinician due to the lack of a standardized protocol for its treatment. Herein we discuss primary small cell carcinoma of the urinary bladder in its entirety.

show abstract

Small cell carcinoma of the bladder and prostate

Cited by 170 publications

References 91 publications

Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder

Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder

Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Primary Small Cell Carcinoma of the Urinary Bladder - Mini-review of the Literature

Contact Info

Product

Resources

About